Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of Afatinib intermediate and its synthetic method

A synthetic method, the technology of afatinib, which is applied in the field of afatinib intermediates and its synthesis, can solve the problems of large loss, difficult removal, and many impurities, and achieve the effects of low cost, less impurities, and reduced losses

Active Publication Date: 2020-12-29
SHANDONG NEWTIME PHARMA
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] The chiral intermediate S-3-hydroxy-tetrahydrofuran is more expensive and will be lost in subsequent multi-step reactions;
[0009] The final product I produced by the Wittig-Horner-Emmons reaction carried out with intermediate 3 has more impurities and is difficult to remove

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of Afatinib intermediate and its synthetic method
  • A kind of Afatinib intermediate and its synthetic method
  • A kind of Afatinib intermediate and its synthetic method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] first step:

[0044] Take 3.4g compound V, 153mgFeCl 3, 50mL of a mixed solution of tert-butanol and acetone (tert-butanol: acetone volume ratio is 3:4) was put into a one-mouth bottle, started electromagnetic stirring, replaced air with nitrogen 3 times, replaced nitrogen with hydrogen 3 times, kept the temperature and pressure for 4 hours, and reacted After completion, the catalyst was removed by suction filtration under reduced pressure, the filtrate was rotary evaporated to dryness, and dried to obtain intermediate IV with a yield of 99.6%.

[0045] Step two:

[0046] Take 2.0g of diethylphosphonoacetic acid and 50ml of tetrahydrofuran into a 250ml three-neck flask, start stirring, slowly add 2.0g of CDI, keep it at 40°C for 1 hour, then add 3.0g of intermediate IV, keep it warm for 1 hour, after the reaction is complete, a large amount of solids are precipitated , and then added 50ml of methyl tert-butyl ether, stirred for 1 h, filtered with suction, and dried to...

Embodiment 2

[0053] first step:

[0054] Take 3.4g of compound V, 102mg of 10% Pd / C, and 50mL of methyl tert-butyl ether into a one-mouth bottle, start electromagnetic stirring, replace the air with nitrogen three times, replace the nitrogen with hydrogen three times, and keep the temperature and pressure for 4 hours. The catalyst was removed by pressure filtration, and the filtrate was rotary evaporated to dryness, and dried to obtain intermediate IV with a yield of 99.1%.

[0055] Step two:

[0056] Take 2.0g of diethylphosphonoacetic acid and 50ml of methyl tert-butyl ether into a 250ml three-necked bottle, start stirring, slowly add 4.5g of CDI, keep it at 40°C for 1 hour, then add 3.0g of intermediate IV, continue to keep it warm for 1 hour, and react After completion, a large amount of solids were precipitated, and then 50ml of methyl tert-butyl ether was added, stirred for 1 hour, filtered with suction, and dried to obtain intermediate III with a yield of 97.1%.

[0057] third ste...

Embodiment 3

[0063] first step:

[0064] Take 3.4g compound V, 170mgFe(OH) 3 , put 100mL of acetone into a single-necked bottle, start electromagnetic stirring, replace air with nitrogen 3 times, replace nitrogen with hydrogen 3 times, heat-preserve and pressurize for 6 hours, after the reaction is completed, remove the catalyst by vacuum filtration, and the filtrate is rotary evaporated to dryness, and dried to obtain the intermediate Ⅳ, the yield is 99.0%.

[0065] Step two:

[0066] Take 2.0g of diethylphosphonoacetic acid and 80ml of methanol into a 250ml three-neck flask, start stirring, slowly add 0.9g of DCC, keep it at 40°C for 1 hour, then add 3.0g of intermediate IV, keep it warm for 1 hour, after the reaction is complete, a large amount of solid, then add 50ml of methanol, stir for 1 hour, filter with suction, and dry to obtain Intermediate III with a yield of 96.2%.

[0067] third step:

[0068] Firstly, dimethylaminoacetaldehyde diethyl acetal is deprotected to generate di...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a novel afatinib intermediate IV and a preparation method thereof. The preparation method comprises a step of reducing N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitro-4-quinazolinamine into N-(3-chloro-4-fluorophenyl)-7-fluoro-6-amino-4-quinazolinamine IV. The method of the invention has high yield and high purity.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, and in particular relates to an afatinib intermediate and a synthesis method thereof. Background technique [0002] Afatinib maleate is a multi-targeted oral small-molecule drug developed by Boehringer Inheim in Germany. It is an epidermal growth factor receptor (EGFR) and human epidermal receptor 2 (HER2) receptor Irreversible inhibitor of amino acid kinases. It is a second-generation highly potent dual irreversible tyrosine kinase inhibitor. The drug was approved by the US FDA on July 12, 2013. The trade name is Gilotrif. [0003] Afatinib maleate (I), the chemical name is 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1- Oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline dimaleate. [0004] [0005] The original Chinese patent CN1867564B of Boehringer Ingelheim Company reported the preparation method of afatinib: the mother nucleus 4-[(3-chloro-4-fluoro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D239/94
CPCC07D239/94
Inventor 张贵民赵绪亮王秀娟
Owner SHANDONG NEWTIME PHARMA